Simponi (Golimumab) (Rheumatoid Arthritis) Market Key Trends, Vendor Strategies Market Analysis and Forecast 2016

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

J&J's Simponi (golimumab) is a fully-human IgG1 mAb specific for TNFa. It inhibits TNFa activity, thereby blocking the inflammatory activity of this cytokine and downstream reactions. Simponi is approved for patients with moderate to severe, active RA, and is typically prescribed in conjunction with MTX as a second line of therapy in patients who have failed treatment with another anti-TNF agent, or who have had an unsatisfactory response to MTX.

Browse Detail Report With TOC @ http://www.hexareports.com/report/simponi-golimumab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023/details

Scope

Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Simponi (golimumab) including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Simponi (golimumab) for the top 8 countries from 2013 to 2023.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia....